Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Therapy entities : Gilead sciences, inc. save search
Kite Receives U.S. FDA Approval of Manufacturing Process Change Resulting in Reduced Median Turnaround Time for Yescarta® CAR T-cell Therapy
Published: 2024-01-30 (Crawled : 15:00) - biospace.com/
GILD | $67.64 -0.16% 1.2M
|
Health Technology
|
| O: -0.34%
H: 0.13%
C: -0.23%
yescarta fda t-cell change approval therapy
Global CAR T-Cell Therapy Market Analysis Report 2023: Drug type, Indication, Target Antigen, End-user and Region - Forecast to 2030
Published: 2024-01-24 (Crawled : 17:00) - prnewswire.com
PFE A | $25.84 -0.27% 8.9M
|
Health Technology
|
| O: 0.39%
H: 0.82%
C: -0.74%
NVS | $93.29 -1.19% 530K
|
Health Technology
|
| O: 0.22%
H: 0.43%
C: -0.39%
GILD | $67.64 -0.16% 1.2M
|
Health Technology
|
| O: 0.1%
H: 0.43%
C: -0.04%
AUTL | $4.94 0.82% 210K
|
Health Technology
|
| O: -0.91%
H: 11.52%
C: 4.94%
drug report t-cell global therapy market
Analyses of Kite’s Yescarta® CAR T-Cell Therapy Support Curative Potential in Patients With Non-Hodgkin Lymphomas
Published: 2023-12-12 (Crawled : 07:00) - biospace.com/
GILD | $67.64 -0.16% 1.2M
|
Health Technology
|
| O: 0.86%
H: 0.49%
C: 0.05%
yescarta t-cell lymphomas potential therapy
Long-Term Data for Kite’s Yescarta® CAR T-Cell Therapy Presented at ASH 2023 Demonstrate High Rate of Durable Response in Patients With High-Risk Large B-Cell Lymphoma
Published: 2023-12-11 (Crawled : 00:00) - biospace.com/
GILD | $67.64 -0.16% 1.2M
|
Health Technology
|
| O: 0.77%
H: 1.52%
C: 0.58%
yescarta t-cell response therapy
Gilead and Kite Oncology Present Data Demonstrating Car T-cell Therapy Survival Benefit and Showcasing Latest Advances in Blood Cancer Portfolio at ASH 2023
Published: 2023-11-02 (Crawled : 14:00) - biospace.com/
GILD | $67.64 -0.16% 1.2M
|
Health Technology
|
| O: -0.47%
H: 1.88%
C: 1.78%
t-cell cancer blood therapy
Kite’s Car T-cell Therapy Yescarta® Demonstrates High Response Rate and Durable Remission in ALYCANTE Study as Initial Treatment for Transplant Ineligible Patients With Relapsed/Refractory Large B-cell Lymphoma
Published: 2023-09-18 (Crawled : 09:00) - biospace.com/
GILD | $67.64 -0.16% 1.2M
|
Health Technology
|
| O: 0.25%
H: 0.38%
C: -0.32%
yescarta t-cell treatment response therapy study
CAR T-Cell Therapy Market size to grow at a CAGR of 13.44% from 2022 to 2027; Growing Awareness Regarding CAR T-cell Therapy to boost the market growth- Technavio.
Published: 2023-08-09 (Crawled : 08:00) - prnewswire.com
GLAXF | $20.2 510
|
Health Technology
|
| O: 1.92%
H: 0.0%
C: 0.0%
NVSEF | $93.6375 82K
|
Health Technology
|
| O: 1.11%
H: 0.53%
C: 0.53%
NVS | $93.29 -1.19% 530K
|
Health Technology
|
| O: -0.07%
H: 0.73%
C: 0.36%
GSK | $39.935 -1.4% 900K
|
Health Technology
|
| O: 0.14%
H: 0.8%
C: 0.43%
GILD | $67.64 -0.16% 1.2M
|
Health Technology
|
| O: 0.61%
H: 1.07%
C: -0.5%
AUTL | $4.94 0.82% 210K
|
Health Technology
|
| O: -2.02%
H: 3.44%
C: 2.75%
t-cell growing therapy market
Kite Announces Completion of Marketing Authorization Transfer for Yescarta® CAR T-cell Therapy in Japan
Published: 2023-06-22 (Crawled : 13:00) - biospace.com/
GILD | $67.64 -0.16% 1.2M
|
Health Technology
|
| O: 0.18%
H: 0.57%
C: 0.46%
yescarta japan transfer t-cell authorization therapy
Kite’s Yescarta® CAR T-cell Therapy Demonstrates Significantly Longer Overall Survival Versus Standard of Care as Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma
Published: 2023-06-05 (Crawled : 17:00) - biospace.com/
GILD | $67.64 -0.16% 1.2M
|
Health Technology
|
| O: -0.09%
H: 0.27%
C: -0.13%
yescarta t-cell treatment care therapy
Gilead and Kite Oncology Demonstrate Growing Hematology Pipeline and Strength of Leading Cell Therapy Portfolio at EHA
Published: 2023-06-01 (Crawled : 13:20) - biospace.com/
GILD | $67.64 -0.16% 1.2M
|
Health Technology
|
| O: 0.78%
H: 0.0%
C: -1.72%
pipeline cell growing therapy
Global HIV Treatment Market Report 2023: Advances in Gene Therapy Present Significant Opportunities for Sector Growth
Published: 2023-05-31 (Crawled : 00:00) - prnewswire.com
GLAXF | $20.2 510
|
Health Technology
|
| O: -0.24%
H: 2.1%
C: 2.1%
VTRS | $11.15 -1.5% 2.3M
|
Health Technology
|
| O: 0.0%
H: 0.66%
C: 0.33%
TEVA | $13.09 -1.06% 3.2M
|
Health Technology
|
| O: 0.42%
H: 0.83%
C: -0.41%
JNJ | $144.56 -2.05% 4.3M
|
Health Technology
|
| O: -0.34%
H: 0.32%
C: 0.0%
GSK | $39.935 -1.4% 900K
|
Health Technology
|
| O: -0.24%
H: 1.43%
C: 0.84%
BMY | $48.365 -0.3% 4.9M
|
Health Technology
|
| O: 0.03%
H: 0.41%
C: 0.34%
ABBV | $163.42 1.08% 2M
|
Health Technology
|
| O: -1.96%
H: 0.0%
C: -1.35%
ABT | $109.92 0.95% 3.2M
|
Health Technology
|
| O: -0.09%
H: 0.97%
C: 0.89%
GILD | $67.64 -0.16% 1.2M
|
Health Technology
|
| O: 0.78%
H: 0.0%
C: -1.72%
report treatment global hiv therapy growth market
Kite’s Yescarta® CAR T-cell Therapy Demonstrates a Statistically Significant Improvement in Overall Survival for Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma
Published: 2023-03-21 (Crawled : 19:00) - biospace.com/
GILD | $67.64 -0.16% 1.2M
|
Health Technology
|
| O: 0.08%
H: 0.66%
C: -0.48%
yescarta t-cell treatment therapy
Kite’s Tecartus® CAR T-Cell Therapy Demonstrates Overall Survival Benefit in Three-Year Follow-up of Pivotal ZUMA-3 Trial in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
Published: 2023-02-09 (Crawled : 13:00) - biospace.com/
GILD | $67.64 -0.16% 1.2M
|
Health Technology
|
| O: 0.19%
H: 0.9%
C: -0.35%
tecartus t-cell leukemia trial therapy
Kite to Acquire Tmunity Therapeutics to Pursue Next Generation CAR T-Cell Therapy Advancements in Cancer
Published: 2022-12-20 (Crawled : 13:20) - biospace.com/
GILD | $67.64 -0.16% 1.2M
|
Health Technology
|
| O: -3.21%
H: 1.93%
C: 1.35%
acquire t-cell therapeutics therapy cancer
Three-Year Follow-Up Analysis of Kite’s Yescarta® CAR T-cell Therapy (ZUMA-5 Trial) - 52% of Patients With Indolent Lymphomas Continued to Have Ongoing Responses at a Median Follow-Up of 40.5 Months
Published: 2022-12-12 (Crawled : 19:00) - biospace.com/
GILD | $67.64 -0.16% 1.2M
|
Health Technology
|
| O: -0.14%
H: 0.81%
C: 0.79%
yescarta ongoing lymphomas t-cell therapy
Kite and Daiichi Sankyo Announce Changes to YESCARTA® CAR T-Cell Therapy Licensing Agreement in Japan
Published: 2022-12-07 (Crawled : 22:00) - biospace.com/
GILD | $67.64 -0.16% 1.2M
|
Health Technology
|
| O: 0.08%
H: 0.59%
C: -0.27%
yescarta japan t-cell agreement therapy
Global Gene Therapy Market Report to 2028 - Industry Analysis, Trends, Market Size and Forecasts
Published: 2022-09-23 (Crawled : 15:20) - prnewswire.com
SNYNF | $92.966 630
|
Health Technology
|
| O: 5.45%
H: 0.0%
C: -8.46%
NVSEF | $93.6375 82K
|
Health Technology
|
| O: 0.27%
H: 0.0%
C: 0.0%
NVS | $93.29 -1.19% 530K
|
Health Technology
|
| O: -1.06%
H: 0.39%
C: -0.41%
SNY | $46.19 0.57% 580K
|
Health Technology
|
| O: -1.69%
H: 0.0%
C: 0.0%
GILD | $67.64 -0.16% 1.2M
|
Health Technology
|
| O: -0.44%
H: 0.46%
C: -0.99%
BIIB | $196.6 -0.1% 350K
|
Health Technology
|
| O: -0.17%
H: 0.17%
C: -1.25%
AMGN | $264.955 -0.21% 880K
|
Health Technology
|
| O: 0.11%
H: 0.27%
C: -0.45%
global report therapy market
Kite’s CAR T-cell Therapy Yescarta® First in Europe to Receive Positive CHMP Opinion for Use in Second-line Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
Published: 2022-09-16 (Crawled : 12:00) - biospace.com/
GILD | $67.64 -0.16% 1.2M
|
Health Technology
|
| O: 0.12%
H: 1.31%
C: 0.8%
yescarta europe chmp t-cell positive therapy
Global Cell Therapy Manufacturing Market to Reach $6.01 Billion by 2026
Published: 2022-09-13 (Crawled : 11:00) - prnewswire.com
TAK | $13.235 0.42% 710K
|
Health Technology
|
| O: -1.17%
H: 0.15%
C: -1.47%
NVS | $93.29 -1.19% 530K
|
Health Technology
|
| O: -0.72%
H: 0.07%
C: -1.27%
CTLT | $56.03 -0.09% 360K
|
Health Technology
|
| O: -2.7%
H: 0.52%
C: -1.7%
GILD | $67.64 -0.16% 1.2M
|
Health Technology
|
| O: -0.9%
H: 0.0%
C: -3.41%
AMGN | $264.955 -0.21% 880K
|
Health Technology
|
| O: -0.25%
H: 0.05%
C: -4.29%
global therapy market
BioLife Solutions Appoints Cell Therapy Executive Timothy L. Moore to its Board of Directors
Published: 2022-08-25 (Crawled : 12:20) - prnewswire.com
GILD | $67.64 -0.16% 1.2M
|
Health Technology
|
| O: 0.36%
H: 0.13%
C: -0.41%
CERS | $1.72 -0.58% 370K
|
Health Technology
|
| O: 1.1%
H: 1.3%
C: 0.43%
BLFS 4 | $16.035 2.26% 210K
|
Health Technology
|
| O: 1.63%
H: 2.4%
C: 2.36%
solutions therapy
Gainers vs Losers
| 53% | 47% |
Top 10 Gainers
WISA 4 | $7.86 349.14% 120M
|
Electronic Technology
TPET | $0.4951 114.24% 29M
|
n/a
PRSO | $1.99 56.69% 52M
|
Manufacturing
PALI | $6.5 56.25% 22M
|
Manufacturing
JAGX | $0.1767 48.74% 430M
|
Health Technology
SXTC | $2.03 45.0% 27M
|
Health Technology
SPCB | $0.3888 40.87% 27M
|
Electronic Technology
DYNT | $0.52 40.39% 20M
|
Health Technology
SNGX | $0.54 39.86% 7.3M
|
Health Technology
BSGM | $1.53 39.09% 2.6M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.